SpringerLink
Log in

La Non Alcoholic Fatty Liver Disease (NAFLD) et la Non Alcoholic Steato-Hepatitis (NASH) des pathologies de système : revue pour le réanimateur

Non Alcoholic Fatty Liver Disease and Non Alcoholic Steato-Hepatitis are multisystemic diseases: Review for intensivists

  • Mise au Point / Update
  • Published:
Médecine Intensive Réanimation

Résumé

La NAFLD (Non Alcoholic Fatty Liver Disease) et la NASH (Non Alcoholic Steato-Hepatitis) sont des maladies de système avec une composante inflammatoire et sont intimement liées au syndrome métabolique, à l’insulinorésistance et à l’obésité. Les atteintes cardiovasculaires sont la première cause de morbimortalité dans la NAFLD, suivies des néoplasies puis des atteintes hépatiques. La recherche biopharmaceutique développe de nouvelles molécules afin de traiter et de reverser la NASH sans aggravation de la fibrose. La NAFLD est l’atteinte hépatique la plus fréquente dans les pays développés et va devenir la première cause de greffe hépatique aux États-Unis d’Amérique dans un avenir proche. Elle représente à ce titre un intérêt majeur pour le médecin réanimateur.

Abstract

NAFLD and NASH are multisystemic disease linked to metabolic syndrom, insulin resistance and obesity. Cardiovascular abnormalities are common in NAFLD and are the principal cause of mortality in the disease, follow by neoplasia and liver complications. The biopharmaceutical research is develop** new target in NASH with the aim of reversion NASH without worsening fibrosis. NAFLD is the most common cause of chronic liver disease in Western countries and should be the first indication for liver transplantation in near years in USA. NAFLD presents as such a major interest for the physician intensivist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64: 73–84

    Article  PubMed  Google Scholar 

  2. Buzzetti E, Pinzani M, Tsochatzis EA, (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65: 1038–1048

    Article  CAS  PubMed  Google Scholar 

  3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ, (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142: 1592–1609

    Article  PubMed  Google Scholar 

  4. Ahmed A, Wong RJ, Harrison SA, (2015) NAFLD review: Diagnosis, treatment and outcomes. Clin Gastroenterolo Hepatol 13: 2062–2070

    Article  Google Scholar 

  5. Bedossa P, (2016) Histological assessment of NAFLD. Dig Dis Sci 61: 1348–1355

    Article  CAS  PubMed  Google Scholar 

  6. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA, (2011) Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141: 1249–1253

    Article  PubMed  Google Scholar 

  7. Patel YA, Berg CL, Moylan CA, (2016) Nonalcoholic Fatty liver disease: Key considerations before and after transplantation. Dig Dis Sci 61: 1406–1416

    Article  CAS  PubMed  Google Scholar 

  8. Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A, (2016) Nonalcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31: 936–944

    Article  CAS  PubMed  Google Scholar 

  9. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ, (2010) The metabolic syndrome. The Lancet 375: 181–183

    Article  Google Scholar 

  10. Cameron AJ, Boyko EJ, Sicree RA, Zimmet PZ, Söderberg S, Alberti KG, Tuomilehto J, Chitson P, Shaw JE, (2008) Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity 16: 2707–2716

    Article  CAS  PubMed  Google Scholar 

  11. Dhindsa S, Tripathy D, Sanalkumar N, RaviShankar S, Ghanim H, Aljada A, Dandona P, (2005) Free fatty acid-induced insulin resistance in the obese is not prevented by rosiglitazone treatment. J Clin Endocrinol Metab 90: 5058–5063

    Article  CAS  PubMed  Google Scholar 

  12. Mowery NT, Dortch MJ, Dossett LA, Norris PR, Diaz JJ Jr, Morris JA Jr, May AK, (2009) Insulin resistance despite tight glucose control is associated with mortality in critically ill surgical patients. J Intensive Care 24: 242–251

    Article  Google Scholar 

  13. Finney SJ, Zekveld C, Elia A, Evans TW, (2003) Glucose control and mortality in critically ill patients. JAMA 290: 2041–2047

    Article  CAS  PubMed  Google Scholar 

  14. Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, (2003) Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med 31: 359–366

    Article  PubMed  Google Scholar 

  15. Byrne CD, Targher G, (2015) NAFLD: a multisystem disease. J Hepatol 62: S47–S64

    Article  PubMed  Google Scholar 

  16. Mantovani A, Ballestri S, Lonardo A, Targher G, (2016) Cardiovascular disease and myocardial abnormalities in nonalcoholic liver disease. Dig Dis Sci 61: 1246–1267

    Article  PubMed  Google Scholar 

  17. Anstee QM, Targher G, Day CP, (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10: 330–344

    Article  CAS  PubMed  Google Scholar 

  18. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G, (2014) Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20: 1724–1745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hamirani YS, Pandey S, Rivera JJ, Ndumele C, Budoff MJ, Blumenthal RS, Nasir K, (2008) Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 201: 1–7

    Article  CAS  PubMed  Google Scholar 

  20. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K, (2013) A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 230: 258–267

    Article  CAS  PubMed  Google Scholar 

  21. Stepanova M, Younossi ZM, (2012) Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10: 646–650

    Article  PubMed  Google Scholar 

  22. Arslan U, Türkoğlu S, Balcioğlu S, Tavil Y, Karakan T, Cengel A, (2007) Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 18: 433–436

    Article  PubMed  Google Scholar 

  23. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, Chim AM, Yu CM, Yu J, Chan FK, Sung JJ, Chan HL, (2011) Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60: 1721–1727

    Article  CAS  PubMed  Google Scholar 

  24. Kim D, Kim WR, Kim HJ, Therneau TM, (2013) Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57: 1357–1365

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, Magnani JW, Vasan RS, Calderwood AH, Pencina M, Sullivan LM, Ellinor PT, Benjamin EJ, (2013) Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 111: 219–224

    Article  CAS  PubMed  Google Scholar 

  26. Alonso A, Misialek JR, Amiin MA, Hoogeveen, RC, Chen LY, Agarwal SK, Loehr LR, Soliman EZ, Selvin E, (2014) Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 100: 1151–1156

    Article  Google Scholar 

  27. Ozveren O, Izgi C, Eroglu E, Simsek MA, Turer A, Kucukdurmaz Z, Cinar V, Degertekin M, (2016) Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty liver disease. Ultrason Imaging 38: 225–235

    Article  PubMed  Google Scholar 

  28. Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, Chiu HM, Lin HJ, Ho YL, Yang WS, Wu MS, Chen MF, (2015) Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc 4: e001820

    Google Scholar 

  29. Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM, (2010) TNF-alpha and IL-1beta increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium 47: 378–386

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E, (2011) Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 22: 660–670

    Article  PubMed  PubMed Central  Google Scholar 

  31. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G, (1998) Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 27: 28–34

    Article  CAS  PubMed  Google Scholar 

  32. Bonapace S, Valbusa F, Bertolini L, Pichri I, Mantovani A, Rossi A, Zenari L, Barbieri E, Targher G, (2014) Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One 9: e88371

    Article  Google Scholar 

  33. Markus MR, Baumeister SE, Stritzke J, Dörr M, Wallaschofski H, Völzke H, Lieb W, (2013) Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol 33: 1690–1695

    Article  CAS  PubMed  Google Scholar 

  34. Völzke H, Haring R, Lorbeer R, Wallaschofski H, Reffelmann T, Empen K, Rettig R, John U, Felix SB, Dörr M, (2010) Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis 209: 606–610

    Article  PubMed  Google Scholar 

  35. Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho GY, Baik I, Lim HE, Kim EJ, Na JO, Lee JB, Lee SK, Shin C, (2014) Nonalcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100: 938–943

    Article  CAS  PubMed  Google Scholar 

  36. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S, (2006) Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40: 949–955

    Article  PubMed  Google Scholar 

  37. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ, (2015) Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 62: 773–783

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Granér M, Nyman K, Siren R, Pentikäinen MO, Lundbom J, Hakkarainen A, Lauerma K, Lundbom N, Nieminen MS, Taskinen MR, (2015) Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging 8: e001979

    Google Scholar 

  39. Rijzewijk LJ, Van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, De Roos A, Lamb HJ, (2008) Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52: 1793–1799

    Article  PubMed  Google Scholar 

  40. Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, Ragogna F, Canu T, Scifo P, Del Mashio A, Luzi L, (2008) Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47: 51–58

    Article  CAS  PubMed  Google Scholar 

  41. Fintini D, Chinali M, Cafiero G, Esposito C, Giordano U, Turchetta A, Pescosolido S, Pongiglione G, Nobili V, (2014) Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr Metab Cardiovasc Dis 24: 72–74

    Article  CAS  PubMed  Google Scholar 

  42. Sunbul M, Kivrak T, Durmus E, Akin H, Aydin Y, Ergelen R, Yilmaz Y, Agirbasli M, (2015) Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc Ther 33: 294–299

    Article  PubMed  Google Scholar 

  43. Poloz Y, Stambolic V, (2015) Obesity and cancer, a case for insulin signaling. Cell Death and Disease 6: e2037

    Article  Google Scholar 

  44. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ, (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625–1638

    Article  PubMed  Google Scholar 

  45. Angulo P, Kleiner De, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F, (2015) Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterol 149: 389–397

    Article  Google Scholar 

  46. Arase Y, Suzuki F, Kobayashi M, Kawamura Y, Matsumoto N, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto Y, Amakawa K, Tsuji H, Hsieh SD, Kato K, Tanabe M, Ogawa K, Hara S, Kobayashi T, (2011) The development of chronic kidney disease in Japanese patients with nonalcoholic fatty liver disease. Intern Med 50: 1081–1087

    Article  CAS  PubMed  Google Scholar 

  47. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M, (2010) Relationship between kidney function and liver histology in subjects withnonalcoholic steatohepatitis. Clin J Am Soc Nephrol 5: 2166–2171

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM, (2007) Effects of bariatric surgery on mortality in Swedish obese subjects N Engl J Med 357: 741–752

    Article  PubMed  Google Scholar 

  49. Lassailly G, Caiazzo R, Buob, Pigeyre M, Verkindt H, Labreuche J, Raverdy V, Leteurtre E, Dharancy S, Louvet A, Romon M, Duhamel A, Pattou F, Mathurin P, (2015) Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterol 149: 379–388

    Article  Google Scholar 

  50. Hannah WN, Harrison SA, (2016) Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig Dis Sci 61: 1365–1374

    Article  CAS  PubMed  Google Scholar 

  51. Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM, (2015) Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg 19: 429–436

    Article  PubMed  Google Scholar 

  52. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK, (2008) Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 6: 1396–1402

    Article  PubMed  Google Scholar 

  53. Ratziu V, (2016) Novel pharmacotherapy options for Nash. Dig Dis Sci 61: 1398–1405

    Article  CAS  PubMed  Google Scholar 

  54. Laganà AS, Vitale SG, Nigro A, Sofo V, Salmeri FM, Rossetti P, Chiara Rapisarda AM, La Vignera S, Condorelli RS, Rizzo G, Buscema M, (2016) Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives Int J Mol Sci 17: pii:E999

    Article  PubMed  Google Scholar 

  55. Ratziu V, Harrison S, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, on behalf of the GOLDEN-505 Investigator Study Group (2016) Elafibranor, an agonist of the peroxisome proliferator-activated receptor alpha and delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150: 1147–1159

    Article  CAS  PubMed  Google Scholar 

  56. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E, (2015) NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385: 956–965

    Article  CAS  PubMed  Google Scholar 

  57. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K; LEAN trial team., Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN, (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicenter, double-blind, randomized, placebo-controlled phase 2 study. Lancet 387: 679–690

    Article  CAS  PubMed  Google Scholar 

  58. Lassailly G, Caiazzo R, Pattou F, Mathurin P, (2016) Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterol 150: 1835–1848

    Article  Google Scholar 

  59. Afzali A, Berry K, Ioannou GN, (2012) Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 18: 29–37

    Article  PubMed  Google Scholar 

  60. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y, (2014) Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12: 394–402

    Article  PubMed  Google Scholar 

  61. Park CW, Tsai NT, Wong LL, (2011) Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 25: e606–11

    Article  Google Scholar 

  62. Fussner LA, Charlton MR, Heimbach JK, Fan C, Dierkhising R, Coss E, Watt KD, (2014)

  63. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int 34: 1259–1266

  64. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A, (2010) Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol 105: 613–620

    Article  PubMed  Google Scholar 

  65. Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, Upton MP, Reyes JD, Perkins JD, (2010) The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 16: 874–884

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’anesthésie réanimation chirurgicale, centre hospitalier Fleyriat, 900, route de Paris, F-01012, Bourg-en-Bresse, France

    M. Hachemi

  2. Département d’hépatogastroentérologie et maladies du foie, hôpital de la Croix-Rousse, hospices civils de Lyon, Lyon, France

    S. Benmakhlouf & F. Zoulim

  3. Service d’hépatogastroentérologie, centre hospitalier Fleyriat, F-01012, Bourg-en-Bresse, France

    P. Prost

  4. Service de pharmacie, centre hospitalier Fleyriat, F-01012, Bourg-en-Bresse, France

    N. Santolaria

  5. Service de réanimation polyvalente, centre hospitalier Fleyriat, F-01012, Bourg-en-Bresse, France

    X. Tchenio & N. Sedillot

Authors
  1. M. Hachemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Benmakhlouf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Prost
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Santolaria
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X. Tchenio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Sedillot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Zoulim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Hachemi.

Additional information

M. Hachemi, P. Prost, N. Santolaria et N. Sedillot sont membres du CLAN (Comité de Liaison Alimentation Nutrition, Président : Dr M. Hachemi) du centre hospitalier Fleyriat à Bourg-en-Bresse, France

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hachemi, M., Benmakhlouf, S., Prost, P. et al. La Non Alcoholic Fatty Liver Disease (NAFLD) et la Non Alcoholic Steato-Hepatitis (NASH) des pathologies de système : revue pour le réanimateur. Méd. Intensive Réa 26, 63–74 (2017). https://doi.org/10.1007/s13546-016-1253-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13546-016-1253-9

Mots clés

Keywords

Search

Navigation